Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowA European committee has endorsed the use of Eli Lilly and Co.'s erectile dysfunction drug Cialis to treat symptoms tied to an enlarged prostate.
The European Union's Committee for Medicinal Products for Human Use recommended approval of a 5-milligram dose of Cialis for patients with benign prostatic hyperplasia. The European Commission usually decides on the committee's opinion within a month or two, Lilly said Friday. It doesn't have to follow the recommendation but often does.
Benign prostatic hyperplasia, or an enlarged prostate, can cause symptoms like the need to urinate urgently and frequently.
The U.S. Food and Drug Administration approved Cialis last fall for the treatment of symptoms of an enlarged prostate. Regulators also have approved this use in Canada, Mexico and Brazil, among other countries.
Cialis brought in $1.88 billion last year, or 8 percent of Lilly's total revenue, as its fifth-best-selling product.
Shares of the Indianapolis drugmaker closed at $47.46 after rising as high as $47.71 earlier in the day, its highest level in four years.
Please enable JavaScript to view this content.